The Will Rogers phenomenon, breast cancer and race.
Adult
Aged
Aged, 80 and over
Female
Humans
Middle Aged
Academic Medical Centers
/ statistics & numerical data
Black or African American
/ statistics & numerical data
Breast
/ pathology
Breast Neoplasms
/ ethnology
Disease-Free Survival
Follow-Up Studies
Health Status Disparities
Kaplan-Meier Estimate
Mississippi
/ epidemiology
Neoplasm Grading
/ statistics & numerical data
Neoplasm Staging
/ statistics & numerical data
Prognosis
Retrospective Studies
Safety-net Providers
/ statistics & numerical data
Survival Rate
White
Breast cancer
Racial disparities
Will Rogers phenomenon
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
17 May 2021
17 May 2021
Historique:
received:
22
07
2020
accepted:
29
03
2021
entrez:
18
5
2021
pubmed:
19
5
2021
medline:
21
10
2021
Statut:
epublish
Résumé
The Will Rogers phenomenon [WRP] describes an apparent improvement in outcome for patients' group due to tumor grade reclassification. Staging of cancers is important to select appropriate treatment and to estimate prognosis. The WRP has been described as one of the most important biases limiting the use of historical cohorts when comparing survival or treatment. The main purpose of this study is to assess whether the WRP exists with the move from the AJCC 7th to AJCC 8th edition in breast cancer [BC] staging, and if racial differences are manifested in the expression of the WRP. This is a retrospective analysis of 300 BC women (2007-2017) at an academic medical center. Overall survival [OS] and disease-free survival [DFS] was estimated by Kaplan-Meier analysis. Bi and multi-variate Cox regression analyses was used to identify racial factors associated with outcomes. Our patient cohort included 30.3% Caucasians [Whites] and 69.7% African-Americans [Blacks]. Stages I, II, III, and IV were 46.2, 26.3, 23.1, and 4.4% of Whites; 28.7, 43.1, 24.4, and 3.8% of Blacks respectively, in anatomic staging (p = 0.043). In prognostic staging, 52.8, 18.7, 23, and 5.5% were Whites while 35, 17.2, 43.5, and 4.3% were Blacks, respectively (p = 0.011). A total of Whites (45.05% vs. 47.85%) Blacks, upstaged. Whites (16.49% vs. 14.35%) Blacks, downstaged. The remaining, 38.46 and 37.79% patients had their stages unchanged. With a median follow-up of 54 months, the Black patients showed better stage-by-stage 5-year OS rates using 8th edition compared to the 7th edition (p = 0.000). Among the Whites, those who were stage IIIA in the 7th but became stage IB in the 8th had a better prognosis than stages IIA and IIB in the 8th (p = 0.000). The 8th showed complex results (p = 0.176) compared to DFS estimated using the 7th edition (p = 0.004). The WRP exists with significant variability in the move from the AJCC 7th to the 8th edition in BC staging (both White and Black patients). We suggest that caution needs to be exercised when results are compared across staging systems to account for the WRP in the interpretation of the data.
Sections du résumé
BACKGROUND
BACKGROUND
The Will Rogers phenomenon [WRP] describes an apparent improvement in outcome for patients' group due to tumor grade reclassification. Staging of cancers is important to select appropriate treatment and to estimate prognosis. The WRP has been described as one of the most important biases limiting the use of historical cohorts when comparing survival or treatment. The main purpose of this study is to assess whether the WRP exists with the move from the AJCC 7th to AJCC 8th edition in breast cancer [BC] staging, and if racial differences are manifested in the expression of the WRP.
METHODS
METHODS
This is a retrospective analysis of 300 BC women (2007-2017) at an academic medical center. Overall survival [OS] and disease-free survival [DFS] was estimated by Kaplan-Meier analysis. Bi and multi-variate Cox regression analyses was used to identify racial factors associated with outcomes.
RESULTS
RESULTS
Our patient cohort included 30.3% Caucasians [Whites] and 69.7% African-Americans [Blacks]. Stages I, II, III, and IV were 46.2, 26.3, 23.1, and 4.4% of Whites; 28.7, 43.1, 24.4, and 3.8% of Blacks respectively, in anatomic staging (p = 0.043). In prognostic staging, 52.8, 18.7, 23, and 5.5% were Whites while 35, 17.2, 43.5, and 4.3% were Blacks, respectively (p = 0.011). A total of Whites (45.05% vs. 47.85%) Blacks, upstaged. Whites (16.49% vs. 14.35%) Blacks, downstaged. The remaining, 38.46 and 37.79% patients had their stages unchanged. With a median follow-up of 54 months, the Black patients showed better stage-by-stage 5-year OS rates using 8th edition compared to the 7th edition (p = 0.000). Among the Whites, those who were stage IIIA in the 7th but became stage IB in the 8th had a better prognosis than stages IIA and IIB in the 8th (p = 0.000). The 8th showed complex results (p = 0.176) compared to DFS estimated using the 7th edition (p = 0.004).
CONCLUSION
CONCLUSIONS
The WRP exists with significant variability in the move from the AJCC 7th to the 8th edition in BC staging (both White and Black patients). We suggest that caution needs to be exercised when results are compared across staging systems to account for the WRP in the interpretation of the data.
Identifiants
pubmed: 34001038
doi: 10.1186/s12885-021-08125-8
pii: 10.1186/s12885-021-08125-8
pmc: PMC8127271
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
554Références
Breast Cancer Res Treat. 2018 Oct;171(3):737-745
pubmed: 29931426
Breast Cancer Res Treat. 2019 Oct;177(3):537-548
pubmed: 31270761
J Clin Oncol. 2016 Apr 1;34(10):1134-50
pubmed: 26858339
Cancer Manag Res. 2019 Feb 13;11:1433-1442
pubmed: 30863154
Br J Cancer. 2006 Oct 9;95(7):841-7
pubmed: 16969342
J Natl Cancer Inst. 2003 Aug 6;95(15):1105-6
pubmed: 12902436
Eur J Cancer. 2017 Apr;75:284-298
pubmed: 28259011
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
N Engl J Med. 1985 Jun 20;312(25):1604-8
pubmed: 4000199
Breast. 2006 Feb;15(1):3-8
pubmed: 16473737
J Urol. 2008 Jan;179(1):28-33
pubmed: 17997434
Head Neck. 2004 Nov;26(11):972-6
pubmed: 15390200
Cancer J Sci Am. 1998 Jan-Feb;4(1):27-34
pubmed: 9467043
Breast J. 2009 May-Jun;15(3):291-5
pubmed: 19645785
Am J Clin Oncol. 1999 Oct;22(5):436-40
pubmed: 10521053
Prostate Cancer Prostatic Dis. 2017 Jun;20(2):210-215
pubmed: 28094251
Br J Cancer. 2002 Jul 15;87(2):171-4
pubmed: 12107838
Breast Cancer Res Treat. 2014 Jun;145(3):753-63
pubmed: 24794028
CA Cancer J Clin. 2017 Jul 8;67(4):290-303
pubmed: 28294295
Arch Intern Med. 2008 Jul 28;168(14):1541-9
pubmed: 18663166
J Surg Oncol. 2006 Mar 1;93(3):221-7
pubmed: 16482602
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Int J Cancer. 2001 Dec 20;96(6):363-71
pubmed: 11745507
J Natl Compr Canc Netw. 2017 Apr;15(4):433-451
pubmed: 28404755
J Natl Cancer Inst. 2005 Sep 7;97(17):1248-53
pubmed: 16145045
Breast Cancer Res Treat. 2018 Jun;169(2):257-266
pubmed: 29388016
Cancer Epidemiol. 2015 Feb;39(1):115-7
pubmed: 25475062
Ann Surg. 2020 Jan;271(1):169-176
pubmed: 30312199
J Clin Oncol. 2003 Sep 1;21(17):3244-8
pubmed: 12947058
Clin Breast Cancer. 2018 Dec;18(6):e1347-e1352
pubmed: 30078612
Breast. 2018 Aug;40:38-44
pubmed: 29677569